Skip to main content
. 2015 Jan 24;11(1):e1004594. doi: 10.1371/journal.ppat.1004594

Figure 2. rAdVax immunotherapy ameliorated electrical abnormalities of chronically T. cruzi-infected mice.

Figure 2

(A) Chronically Colombian-infected mice (120 dpi) were primed-boosted with 2 × 108 plaque-forming units (PFU) of rAdCtrl or a mixture of 108 PFU of each adenovirus vaccine preparation (rAdASP2+rAdTS; rAdVax) and analyzed for electrocardiogram (ECG) abnormalities at 70 and 110 days post-therapy (dpt). (B) Heart rate (beats per minutes, bpm) and P wave duration (per ms). The data are shown as the means ± SD per group of 7–8 mice. (C) Representative ECG register segments of sex- and age-matched noninfected (NI) controls and T. cruzi-infected mice injected with saline or vaccinated with rAdCtrl or rAdVax at 160 dpi (40 days post-prime) and 230 dpi (110 dpt). (D) Summary of the group data from NI controls and chronically T. cruzi-infected mice injected with saline or vaccinated with rAdCtrl or rAdVax, showing the frequency of mice presenting arrhythmias (ART), second-degree atrioventricular block (AVB2) and afflicted with ECG alterations. * P <0.05, **P <0.01 and ***P <0.001, experimental groups compared with NI controls. # P <0.05, ## P <0.01 and ### P <0.001, rAdVax-immunized compared with pre-therapy T. cruzi-infected mice. § P <0.05, §§ P < 0.01 and §§§ P <0.001, rAdVax-immunized compared with rAdCtrl-injected T. cruzi-infected mice.